Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

NHS Generic Pharmaceuticals - Lenalidomide, Pomalidomide & Thalidomide

NHS England

This public procurement record has 5 releases in its history.

Award

28 May 2026 at 16:58

UK7 - Contract Details Notice
Award

26 Mar 2026 at 12:18

UK6 - Contract Award Notice
Tender

05 Feb 2026 at 15:03

UK4 - Tender Notice
Planning

23 Jan 2026 at 10:29

UK2 - Preliminary Market Engagement Notice
Planning

21 May 2025 at 18:39

UK1 - Pipeline Notice
Summary of the contracting process

The procurement process overview indicates that NHS England has awarded a contract for the procurement of Lenalidomide, Pomalidomide, and Thalidomide under the NHS National Framework Agreement. This open procedure tender falls under the pharmaceuticals industry category and covers regions across the UK, including the Midlands, Southwest, Northwest, London North, London South, and Northeast. The contract period is set from 1st June 2026 to 31st May 2028, with options for extensions up to a total of 48 months. The contract value stands at £19,595,208 (amount net). The framework agreement employs a reopening competition method, adhering to GPA standards, concluded with the award stage being completed and multiple suppliers participating.

This procurement presents substantial profit and growth opportunities for businesses in the pharmaceutical sector, especially those capable of supplying large volumes efficiently and participating in framework agreements. SMEs and larger suppliers alike were successful in securing awards, indicating inclusivity for both enterprise scales. Suitable businesses would be those already within pharmaceutical supply chains or those looking to expand into public sector contracts, enhancing their footprint across the UK. The opportunity highlights the potential for recurring sales and stability through multi-year contracts with NHS England, serving as a springboard for market presence enhancement and business scaling.

How relevant is this notice?

Notice Information

Notice Title

NHS Generic Pharmaceuticals - Lenalidomide, Pomalidomide & Thalidomide

Notice Description

NHS National Framework for Lenalidomide, Pomalidomide & Thalidomide. Offer reference number: CM/PHG/24/5716 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months. Periods of call-offs under the framework agreement: CM/PHG/24/5716/01- NHS National Framework for Lenalidomide, Pomalidomide & Thalidomide. CESW: (Midlands and Southwest): 1st June 2026 - 31st May 2028 NWLN: (Northwest and London North): 1st June 2026 - 31st May 2028 LSNE: (London South and Northeast): 1st June 2026 - 31st May 2028

Lot Information

Lenalidomide

Lenalidomide CESW: (Midlands and Southwest): 1st June 2026 - 31st May 2028 NWLN: (Northwest and London North): 1st June 2026 - 31st May 2028 LSNE: (London South and Northeast): 1st June 2026 - 31st May 2028

Options: option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months.

Renewal: option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months.

Pomalidomide

Pomalidomide CESW: (Midlands and Southwest): 1st June 2026 - 31st May 2028 NWLN: (Northwest and London North): 1st June 2026 - 31st May 2028 LSNE: (London South and Northeast): 1st June 2026 - 31st May 2028

Options: option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months.

Renewal: option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months.

Thalidomide

Thalidomide CESW: (Midlands and Southwest): 1st June 2026 - 31st May 2028 NWLN: (Northwest and London North): 1st June 2026 - 31st May 2028 LSNE: (London South and Northeast): 1st June 2026 - 31st May 2028

Options: option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months.

Renewal: option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months.

Planning Information

NHS England is advising suppliers of an upcoming tender for the NHS Generics Pharmaceuticals – Lenalidomide, Pomalidomide & Thalidomide to commence on 1st June 2026 for 24 months with options to extend for a maximum total contract period of 48 months. This procurement will consist Lenalidomide, Pomalidomide and Thalidomide products across all regions of the country. The purpose of this notice is to inform existing and potential new suppliers of this procurement. Useful information for suppliers can be found here www.england.nhs.uk/medicines-2/medicines-value-and-access/medicines-procurement-and-supply-chain/ . Specific information regarding the products included in this procurement will be provided in the ITO which will be issued shortly.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-051c39
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/050525-2026
Current Stage
Award
All Stages
Planning, Tender, Award

Procurement Classification

Notice Type
UK7 - Contract Details Notice
Procurement Type
Framework
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
SME
Awardee Scale
Large, SME

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
£33,981,928 £10M-£100M
Lots Value
£3 Under £100K
Awards Value
£19,595,208 £10M-£100M
Contracts Value
£19,595,208 £10M-£100M

Notice Dates

Publication Date
28 May 20263 months ago
Submission Deadline
9 Mar 2026Expired
Future Notice Date
2 Feb 2026Expired
Award Date
24 Mar 20265 months ago
Contract Period
1 Jun 2026 - 31 May 2028 2-3 years
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Active, Complete
Awards Status
Active
Contracts Status
Active

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
NHS England
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
LONDON
Postcode
SE1 8UG
Postcode Area
South East London
Country
England
Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI4 Inner London - East
Small Region (ITL 3)
TLI45 Lambeth
Delivery Location
TLC North East (England), TLD North West (England), TLE Yorkshire and The Humber, TLF East Midlands (England), TLG West Midlands (England), TLH East (England), TLI London, TLJ South East (England), TLK South West (England)
Local Authority
Lambeth
Electoral Ward
Waterloo & South Bank
Westminster Constituency
Vauxhall and Camberwell Green

Supplier Information

Number of Suppliers
11
Supplier Names

ACCORD-UK Ltd

Amarox Limited

Lipomed AG

Milpharm Ltd

Reig Jofre UK limited

SUN PHARMA UK LIMITED

Teva UK Limited

Thornton and Ross Ltd

Viatris UK Healthcare Limited

Wockhardt UK Limited

Zentiva Pharma UK Ltd

Further Information

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...